David J Payne

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. ncbi request reprint Drugs for bad bugs: confronting the challenges of antibacterial discovery
    David J Payne
    Infectious Diseases Centre of Excellence for Drug Discovery, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, USA
    Nat Rev Drug Discov 6:29-40. 2007
  2. doi request reprint Microbiology. Desperately seeking new antibiotics
    David J Payne
    Antibacterial Disease Performance Unit, Infectious Diseases Center of Excellence, GlaxoSmithKline, Collegeville, PA 19426, USA
    Science 321:1644-5. 2008
  3. ncbi request reprint Genomic approaches to antibacterial discovery
    David J Payne
    Department of Microbiology, Microbial, Musculoskeletal, Proliferative Diseases Centr for Excellence and Drug Discovery, GlaxoSmithKline, Collegeville, PA, USA
    Methods Mol Biol 266:231-59. 2004
  4. ncbi request reprint Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI)
    William H Miller
    GlaxoSmithKline Pharmaceuticals, 1250 South Collegeville Road, P O Box 5089, Collegeville, PA 19426, USA
    J Med Chem 45:3246-56. 2002
  5. ncbi request reprint The potential of bacterial fatty acid biosynthetic enzymes as a source of novel antibacterial agents
    David J Payne
    Department of Microbiology, GlaxoSmithKline, Collegeville, Pennsylvania, USA
    Drug News Perspect 17:187-94. 2004
  6. pmc Discovery of a novel and potent class of FabI-directed antibacterial agents
    David J Payne
    Microbial, Musculoskeletal and Proliferative Diseases Center of Excellence in Drug Discovery, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania 19426, USA
    Antimicrob Agents Chemother 46:3118-24. 2002
  7. ncbi request reprint Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK
    Mark A Seefeld
    GlaxoSmithKline Pharmaceuticals, 1250 South Collegeville Road, P O Box 5089, Collegeville, Pennsylvania 19426, USA
    J Med Chem 46:1627-35. 2003
  8. pmc Defining and combating the mechanisms of triclosan resistance in clinical isolates of Staphylococcus aureus
    Frank Fan
    Microbial, Musculoskeletal and Proliferative Diseases CEDD Computational and Structural Sciences, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania 19426, USA
    Antimicrob Agents Chemother 46:3343-7. 2002
  9. ncbi request reprint Identification of antimicrobial targets using a comprehensive genomic approach
    Dezhong Yin
    Department of Microbiology, GlaxoSmithKline Pharmaceuticals Research and Development, Collegeville, PA 19462, USA
    Pharmacogenomics 5:101-13. 2004
  10. doi request reprint Challenges of antibacterial discovery revisited
    Michael N Gwynn
    Antibacterial Discovery Performance Unit, Infectious Diseases Center of Excellence for Drug Discovery, GlaxoSmithKline, Collegeville, Pennsylvania, USA
    Ann N Y Acad Sci 1213:5-19. 2010

Collaborators

Detail Information

Publications13

  1. ncbi request reprint Drugs for bad bugs: confronting the challenges of antibacterial discovery
    David J Payne
    Infectious Diseases Centre of Excellence for Drug Discovery, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, USA
    Nat Rev Drug Discov 6:29-40. 2007
    ....
  2. doi request reprint Microbiology. Desperately seeking new antibiotics
    David J Payne
    Antibacterial Disease Performance Unit, Infectious Diseases Center of Excellence, GlaxoSmithKline, Collegeville, PA 19426, USA
    Science 321:1644-5. 2008
  3. ncbi request reprint Genomic approaches to antibacterial discovery
    David J Payne
    Department of Microbiology, Microbial, Musculoskeletal, Proliferative Diseases Centr for Excellence and Drug Discovery, GlaxoSmithKline, Collegeville, PA, USA
    Methods Mol Biol 266:231-59. 2004
    ....
  4. ncbi request reprint Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI)
    William H Miller
    GlaxoSmithKline Pharmaceuticals, 1250 South Collegeville Road, P O Box 5089, Collegeville, PA 19426, USA
    J Med Chem 45:3246-56. 2002
    ..Taken together, these results support FabI as a valid antibacterial target and demonstrate the potential of small-molecule FabI inhibitors for the treatment of bacterial infections...
  5. ncbi request reprint The potential of bacterial fatty acid biosynthetic enzymes as a source of novel antibacterial agents
    David J Payne
    Department of Microbiology, GlaxoSmithKline, Collegeville, Pennsylvania, USA
    Drug News Perspect 17:187-94. 2004
    ..The fatty acid biosynthetic pathway is an essential metabolic process in bacteria and presents several novel targets for antibiotic development...
  6. pmc Discovery of a novel and potent class of FabI-directed antibacterial agents
    David J Payne
    Microbial, Musculoskeletal and Proliferative Diseases Center of Excellence in Drug Discovery, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania 19426, USA
    Antimicrob Agents Chemother 46:3118-24. 2002
    ..aureus infections that are resistant to our present armory of antibiotics...
  7. ncbi request reprint Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK
    Mark A Seefeld
    GlaxoSmithKline Pharmaceuticals, 1250 South Collegeville Road, P O Box 5089, Collegeville, Pennsylvania 19426, USA
    J Med Chem 46:1627-35. 2003
    ..The results described herein support the hypothesis that bacterial enoyl-ACP reductases are valid targets for antibacterial agents...
  8. pmc Defining and combating the mechanisms of triclosan resistance in clinical isolates of Staphylococcus aureus
    Frank Fan
    Microbial, Musculoskeletal and Proliferative Diseases CEDD Computational and Structural Sciences, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania 19426, USA
    Antimicrob Agents Chemother 46:3343-7. 2002
    ..aureus, and we present three compounds from a novel chemical series of FabI inhibitors which have excellent activities against both triclosan-resistant and -sensitive clinical isolates of S. aureus...
  9. ncbi request reprint Identification of antimicrobial targets using a comprehensive genomic approach
    Dezhong Yin
    Department of Microbiology, GlaxoSmithKline Pharmaceuticals Research and Development, Collegeville, PA 19462, USA
    Pharmacogenomics 5:101-13. 2004
    ..This data demonstrates that a regulated antisense RNA expression library provides an effective tool to assist in the identification of potential targets for novel antibacterial agents...
  10. doi request reprint Challenges of antibacterial discovery revisited
    Michael N Gwynn
    Antibacterial Discovery Performance Unit, Infectious Diseases Center of Excellence for Drug Discovery, GlaxoSmithKline, Collegeville, Pennsylvania, USA
    Ann N Y Acad Sci 1213:5-19. 2010
    ..Implementing multiple screening and target identification strategies is recommended for improving the likelihood of discovering new antibacterial compounds that address unmet needs...
  11. ncbi request reprint Novel antibacterials: a genomics approach to drug discovery
    Pan F Chan
    Department of Microbiology Microbial, Musculoskeletal and Proliferative Diseases CEDD, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426 0989, USA
    Curr Drug Targets Infect Disord 2:291-308. 2002
    ..Genomics can also increase the chemical diversity against which the novel targets can be screened...
  12. pmc Identification of a series of tricyclic natural products as potent broad-spectrum inhibitors of metallo-beta-lactamases
    David J Payne
    Microbial, Musculoskeletal and Proliferative Diseases CEDD UP1345, GlaxoSmithKline, Collegeville, Pennsylvania 19426 0989, USA
    Antimicrob Agents Chemother 46:1880-6. 2002
    ..Consequently, this series of metallo-beta-lactamase inhibitors exhibit the most promising antibacterial synergy activity so far observed against organisms producing metallo-beta-lactamases...
  13. pmc Characterization of Streptococcus pneumoniae enoyl-(acyl-carrier protein) reductase (FabK)
    Hedia Marrakchi
    Protein Science Division, Department of Infectious Disease, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Biochem J 370:1055-62. 2003
    ..The restricted occurrence of the FabK enoyl-ACP reductase may be related to the role of substrate-independent NADH oxidation in oxygen-dependent anaerobic energy metabolism...